Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease - MIRACLE

Study identifier:D6402C00001

ClinicalTrials.gov identifier:NCT04595370

EudraCT identifier:2020-003126-23

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2b, Randomised, Double-Blind, Active Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients with Heart Failure and Chronic Kidney Disease

Medical condition

heart failure

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD9977, Dapagliflozin

Sex

All

Actual Enrollment

153

Study type

Interventional

Age

21 Years - 130 Years

Date

Study Start Date: 26 Jan 2021
Primary Completion Date: 22 Sept 2023
Study Completion Date: 22 Sept 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria